David Y. Liu is CSO at Protagonist Therapeutics, Inc (PTGX). They have made 7 open-market trades across 1 company since 2017, most recently 2022-11-16.
CIK 0001675881
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PTGX | 80,878 | $11.6M |
Shares reported on the most recent Form 4, priced at the 2022-11-17 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PTGX | SELL | 2021-08-17 | 2021-08-19 | $47.56 | $1.4M | +1.0% | -73.0% | -24.2% |
| PTGX | SELL | 2019-08-06 | 2019-08-08 | $8.85 | $30K | +19.7% | +68.5% | +18.0% |
| PTGX | SELL | 2019-03-01 | 2019-03-04 | $8.03 | $7K | +13.8% | +42.9% | +11.8% |
| PTGX | SELL | 2019-02-06 | 2019-02-08 | $7.74 | $30K | +3.4% | +33.1% | +53.2% |
| PTGX | SELL | 2018-03-12 | 2018-03-13 | $21.29 | $75K | -1.6% | -56.3% | -65.3% |
| PTGX | SELL · 10b5-1 | 2018-03-02 | 2018-03-02 | $20.00 | $18K | -0.4% | -59.6% | -64.5% |
| PTGX | SELL · 10b5-1 | 2018-01-16 | 2018-01-17 | $20.00 | $18K | +11.5% | -9.9% | -53.9% |
| PTGX | SELL · 10b5-1 | 2017-12-18 | 2017-12-20 | $20.00 | $18K | +9.0% | -1.5% | +6.7% |
| PTGX | SELL · 10b5-1 | 2017-11-30 | 2017-12-01 | $20.00 | $18K | -4.7% | +11.0% | -8.7% |
| PTGX | SELL | 2017-11-13 | 2017-11-15 | $16.97 | $119K | +15.6% | +14.7% | +5.1% |
| PTGX | SELL | 2017-08-28 | 2017-08-29 | $15.00 | $53K | -12.4% | +7.5% | +15.5% |
| PTGX | SELL · 10b5-1 | 2017-07-10 | 2017-07-12 | $12.68 | $44K | +0.8% | -16.5% | +47.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.